Orforglipron trial results: what the ATTAIN-1 data actually shows

What did @chrisdaghermd actually say?

Dr. Dagher covered the ATTAIN-1 phase 3 trial for orforglipron, Eli Lilly's oral GLP-1 receptor agonist. He reported that the 36 mg dose produced "a 12.4% drop in weight" at 72 weeks, roughly 27 pounds, and that "almost 40% of the patients on the 36 milligram dose" lost more than 15% of their body weight. He noted cardiometabolic improvements including a "reduction in their inflammation by almost 50%." He also compared the drug to tirzepatide, citing "21-22% weight loss" for the injectable, and speculated orforglipron could seek FDA approval around 2026. His main thesis: this is the first oral pill with genuinely effective weight loss results.

Does the science back this up?

Mostly, yes. The ATTAIN-1 trial data, published in the New England Journal of Medicine in 2025, largely supports what he said. The 36 mg orforglipron arm did achieve approximately 12.4% mean body weight reduction versus around 2% for placebo at 72 weeks. That is a clinically meaningful difference. The cardiometabolic signal, including improvements in lipids, blood pressure, and C-reactive protein, is real and consistent with what you see across the GLP-1 drug class.

Where things get slightly fuzzy is the inflammation claim. A "50% reduction in inflammation" sounds dramatic, but C-reactive protein reductions in GLP-1 trials are partly driven by weight loss itself, not a direct anti-inflammatory drug effect. That distinction matters when you're talking to patients about why this drug works. The ATTAIN-1 investigators (Jastreboff et al., 2025, NEJM) were careful to note this, even if a TikTok summary can't be expected to go that deep.

What did they get wrong (or right)?

The tirzepatide comparison deserves scrutiny. Dagher says injections are "probably more effective" and cites "21-22% weight loss" for tirzepatide at roughly the same time interval. That figure is in the right neighborhood for the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM), where the highest dose hit around 20.9% at 72 weeks. But comparing two different drugs across two different trials, with different populations, different baseline weights, and different designs, is not a clean apples-to-apples comparison. He hedges appropriately with the word "roughly," but listeners may walk away thinking orforglipron is simply the inferior, cheaper option. The reality is more complicated.

His framing that this is "the first oral pill with really effective weight loss" also warrants a small asterisk. Oral semaglutide (Rybelsus, later Wegovy oral formulation) exists, though its efficacy data at approved doses has historically lagged behind injectable semaglutide. Orforglipron's oral bioavailability mechanism differs and appears more dose-consistent, so the claim has merit, but calling it the unambiguous first is slightly overstated.

Credit where it is due: he correctly identifies ATTAIN-1 as a randomized placebo-controlled trial across multiple countries, accurately reports the headline efficacy numbers, and honestly acknowledges the injection-versus-pill trade-off without overselling either option.

What should you actually know?

Orforglipron is not approved yet. Phase 3 data is the step before FDA submission, and regulatory review takes time. A 2026 approval is plausible based on Lilly's stated timeline, but that is not guaranteed. The drug still needs to clear the full regulatory process.

The 12.4% average weight loss figure is a mean. That means half the patients lost less. Patient-level variation in GLP-1 response is real and driven by factors including adherence, baseline metabolic health, diet, and genetic differences in GLP-1 receptor expression. "Almost 40% lost over 15%" is genuinely impressive, but it also means the majority did not hit that threshold.

Side effect profile matters. Like other GLP-1 agonists, orforglipron's trial showed gastrointestinal adverse events, nausea, vomiting, diarrhea, as the most common reasons for discontinuation. Dagher did not cover this in detail, which is a notable omission for a clinical summary aimed at patients weighing treatment options.

If you are considering any GLP-1 therapy, the conversation belongs with a clinician who has access to your full health history, not a 60-second video, including this one.